Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Trial ID or NCT#
NCT00490529
Status
NOT RECRUITING
Purpose
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.
Official Title
Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma
Eligibility Criteria
Ages Eligible for Study: 21 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Sandra Horning
Sally Arai
Blood and marrow transplant specialist,
Hematologist,
Blood and marrow transplant specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Blood and marrow transplant specialist,
Hematologist,
Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Wen-Kai Weng, MD, PhD
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Lymphoma specialist,
Medical oncologist,
Multiple myeloma specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Ash A. Alizadeh, MD/PhD
Medical oncologist,
Lymphoma specialist,
Cancer geneticist
Moghadam Family Professor
Michael Khodadoust
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist,
Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov